Psychedelic Harm Reduction

Lieferzeit: Lieferbar innerhalb 14 Tagen

181,89 

Current Topics in Behavioral Neurosciences 77

ISBN: 3032211069
ISBN 13: 9783032211064
Herausgeber: Tomislav Majic
Verlag: Springer Verlag GmbH
Umfang: xvii, 567 S., 50 s/w Illustr., 40 farbige Illustr., 567 p. 90 illus., 40 illus. in color.
Erscheinungsdatum: 05.05.2026
Auflage: 1/2026
Produktform: Gebunden/Hardback
Einband: Gebunden
Artikelnummer: 9687640 Kategorie:

Beschreibung

Classic psychedelics such as psilocybin, LSD, ayahuasca, 5-MeO-DMT, and mescaline are multifaceted substances that have been used for healing and ritual purposes for millennia. In recent years, scientific interest in their therapeutic potential has resurged, yielding promising results for the treatment of mental health conditions, including depression, anxiety, and substance use disorders. At the same time, growing public interest and enthusiastic media coverage have contributed to increasing use in non-clinical contexts. Although psychedelics are considered not addictive and exhibit very low toxicity, their use can, in some cases, be associated with considerable risks and complications. To date, these risks remain underresearched, and many mental health professionals are insufficiently informed about their pathophysiology, differential diagnosis and clinical management. This book seeks to address this gap. From an interdisciplinary perspective, it aims to contribute to a more nuanced and balanced understanding of the benefit-risk ratio and to offer practical guidance for managing complications that may arise when psychedelics are used in therapy and beyond.   The chapter "Classifying Psychedelic-Related Complications" is available open access under the Creative Commons Attribution Non Commercial - No Derivatives 4.0 International License via link.springer.com.

Autorenporträt

Dr. med. Tomislav Majic: Licensed psychiatrist and psychotherapist in Berlin, Germany, with a focus on psychosis, substance use, double diagnosis and harm reduction. Studied medicine at Charité University Clinic Berlin until 2005. Co-founder and lead of Psychedelic Substances Research Group" at Charité. Lecturer and supervisor for psychodynamic therapy at Berlin Institute for Psychotherapy and Psychoanalysis (BIPP). Founder of day clinic for patients with double diagnoses (2017) and outpatient treatment for patients suffering from psychedelic-related disorders (2017) ("Ambulanz Psychedelische Substanzen") at Psychiatric University Clinic of Charité at Hospital St. Hedwig Berlin. Study therapist and researcher  investigating therapeutic effects of classic psychedelics as well as psychedelic-related complications

Herstellerkennzeichnung:


Springer Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

E-Mail: juergen.hartmann@springer.com

Das könnte Ihnen auch gefallen …